Dana Hosseini
A serial entrepreneur who has managed and co-founded a number of genomics-based companies including, ProdermIQ, Iceland Genomics and DiThera. Mr. Hosseini's skills in international medical device/diagnostic sales and marketing were developed at Abbott Laboratories, Ortho Clinical Diagnostics (Johnson & Johnson) and Sequenom, where he held executive and management positions in business development, and sales and marketing functions. He has 25+ years of extensive experience working with global biotech, pharmaceutical companies and healthcare providers. He received both his B.Sc. and MBA from the University of British Columbia.
Marisa Meloni Ph.D
Marisa Meloni got a PhD in Drug Delivery and Cutaneous Bio-physic at Renée Descartes University, Paris V (France). Thereafter, she was in charge for research and innovation within the dermo-pharmaceutical and cosmetic industry for 15 years. During that period, she also was contract professor of safety assessment and technology of cosmetic products at Milan, Salerno and Padua Universities.
In 2001, she created VitroScreen, a research laboratory committed to in vitro science that has the mission to be a reference partner for companies approaching in vitro alternatives, providing in vitro pre-clinical efficacy and regulatory toxicological services.
At VitroScreen she has developed “mechanism based experimental models“ on 3D reconstructed human tissue models for active ingredients and finished product testing: this approach better mimics the in vivo skin and epithelia response taking into account the dynamic of the biological response. VitroScreen is GLP certified and a member of the EU-Netval national reference laboratory network.
Constantin Rojahn
Constantin joined BlueGem Capital Partners as an Investment Manager in 2017.
He is involved in deal sourcing and deal execution across Europe and is on the Board of QMS Medicosmetics.
Prior to joining BlueGem, Constantin spent nearly four years at TA Associates, with a focus on investments in the consumer sector across Europe. Constantin started his career in Investment Banking at Goldman Sachs in London.
Constantin holds a BA in Economics & Management from Bocconi University in Milan.
Chris Hand
Dr Chris Hand has 30 years’ experience in the medical diagnostics industry in the development and commercialisation of in vitro diagnostic products. Chris co-founded the medical diagnostics company Cozart Bioscience Ltd and was Chief Executive of Cozart plc, following IPO on AIM in 2004, until October 2007 when the company was sold to Concateno plc for £65 million. Chris was a non-executive director of Concateno plc until its sale to US listed Alere Inc for £147m in August 2009 and stayed with the company as consultant until June 2010. Prior to founding Cozart, Chris was Director of Research for the European base of DPC (now part of Siemens Healthcare Solutions) developing a wide range of immunodiagnostic kits in a variety of formats.
Chris was a non-executive director of Advanced Computer Software plc, the AIM-listed leading software and IT services provider until the sale to Vista Private Equity for £750m in March 2015.
He has a BSc in Applied Biochemistry from Brunel University and a DPhil from the Faculty of Medicine, University of Oxford.
Alessandro Della Chà
Italian (born 1963), has been a Board Member of Cosmo Pharmaceuticals S.A. since 2006 and
is the CEO as of 27 March 2014.
Until 27 March 2014, he was senior partner at Studio Legale Edoardo Ricci e Associati, Milan,
where he specialized in company law, mergers and acquisitions. He joined the firm in 1988.
From 1987 to 1988 he was assistant of the central director for corporate matters at Fininvest
Group. From 1994 to 1998 he was director of II.PP.A.B. Milan (formerly ECA), a charitable
institution owning hospitals and specialized in elderly care.
Alessandro Della Chà has a degree in law from the University of Milan, Italy, and an LL.M. in
European Union commercial law from the University of Leicester, United Kingdom. He is a
lecturer in conferences and seminars held by universities and institutions on commercial and
company law issues.
Liana Steeghs
Liana Steeghs is CEO at Immuno Valley. She has an entrepreneurial spirit, is an excellent matchmaker and has a proven track record in acquisition of funding and establishing R&D partnerships in the field of infectious diseases. Before Immuno Valley, she worked for 15 years as a scientist in knowledge and applied technology institutes in the Netherlands and the UK. From her personal drive to contribute to the health of humans and animals, she specialized in bacterial vaccinology and immune mechanisms aiming at prevention of infectious diseases. Liana was trained in Biotechnology, followed by a PhD in Molecular Microbiology at Utrecht University. In addition, she holds a degree in Program management and completed the RSM Diploma programme in Business management and Leadership.
